Increased Population Risk of *AIP*-related Acromegaly and Gigantism in Ireland

Serban Radian[1,2], Yoan Diekmann[3], Plamena Gabrovska[1], Brendan Holland[1], Lisa Bradley[4], Helen Wallace[5], Karen Stals[6], Anna-Marie Bussell[6], Karen McGurren[7], Martin Cuesta[7], Anthony W. Ryan[8], Maria Herincs[1], Laura C. Hernández-Ramírez[1], Aidan Holland[1], Jade Samuels[1], Elena Daniela Aflorei[1], Sayka Barry[1], Judit Dénes[1], Ida Pernicova[1], Craig E. Stiles[1], Giampaolo Trivellin[1], Ronan McCloskey[1], Michal Azjensztejn[9], Noina Abid[9], Scott A. Akker[1], Moises Mercado[10], Mark Cohen[11], Rajesh V. Thakker M.D., Sc.D.[12], Stephanie Baldeweg[13], Ariel Barkan[14], Madalina Musat[2], Miles Levy[15], Steve Orme[16], Martina Unterländer[17], Joachim Burger[17], Ajith V. Kumar[18], Sian Ellard[6], Joseph McPartlin[19], Ross McManus[8], Gerard J. Linden[20], Brew Atkinson[5], David Balding[3,21], Amar Agha[7], Chris J. Thompson[7], Steven J. Hunter[5], Mark G. Thomas[3], Patrick J Morrison[4,22], Márta Korbonits[1]

[1]*Centre of Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom*

[2]*Department of Endocrinology, Carol Davila University of Medicine and Pharmacy, C.I. Parhon National Institute of Endocrinology, Bucharest 011863, Romania*

[3]*Research Department of Genetics, Evolution and Environment, University College London, London, United Kingdom*

[4]*Department of Medical Genetics, Belfast HSC Trust*

[5]*Regional Centre for Endocrinology and Diabetes, Royal Victoria Hospital, Belfast, United Kingdom*

[6]Department of Molecular Genetics, Royal Devon and Exeter NHS Foundation Trust/ Institute of Biomedical and Clinical Science, University of Exeter Medical School, Exeter, United Kingdom

[7]Department of Endocrinology and Diabetes, Beaumont Hospital/RCSI Medical School, Dublin, Ireland

[8]Department of Clinical Medicine and Institute of Molecular Medicine, Trinity College Dublin, Trinity Centre for Health Sciences, St James's Hospital, Dublin, Ireland

[9]Royal Belfast Hospital for Sick Children, Belfast, United Kingdom

[10]Endocrinology Service/Experimental Endocrinology Unit, Hospital de Especialidades, Centro Medico Nacional Siglo XXI, IMSS, Mexico City, Mexico

[11]Department of Endocrinology and Diabetes, Barnet General Hospital, London, United Kingdom

[12]Academic Endocrine Unit, OCDEM, University of Oxford, Oxford, United Kingdom

[13]Department of Endocrinology and Diabetes, University College London Hospitals, London, United Kingdom

[14]Department of Neurosurgery, University of Michigan, Ann Arbor, Michigan, United States of America

[15]Department of Endocrinology, University Hospitals of Leicester, Leicester, United Kingdom

[16]Department of Endocrinology, St James's University Hospital, Leeds, United Kingdom

[17]Institute of Anthropology, Johannes Gutenberg University, Mainz, Germany

[18]North East Thames Regional Genetics Service, Great Ormond Street Hospital, London, United Kingdom

[19]Trinity Biobank, Institute of Molecular Medicine, Trinity College Dublin, Trinity Centre for Health Sciences, St James's Hospital, Dublin, Ireland

[20]Centre for Public Health, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, United Kingdom

[21]Schools of Biosciences and of Mathematics & Statistics, University of Melbourne, Parkville, Victoria, Australia

[22] *Centre for Cancer Research and Cell Biology, Queens University Belfast, Belfast, United Kingdom*

Short title: *Increased Population Risk of Gigantism in Ireland*

Corresponding author:

Márta Korbonits MD, PhD

Department of Endocrinology

Barts and the London School of Medicine

Queen Mary University of London

Charterhouse Square

London EC1M 6BQ

Tel +44 20 7882 6238, Fax+44 20 7882 6197

 E-mail: m.korbonits@qmul.ac.uk

Abstract

The aryl hydrocarbon receptor interacting protein (*AIP*) founder mutation R304* (or p.R304*; NM_003977.3:c.910C>T, p.Arg304Ter) identified in Northern Ireland (NI) predisposes to acromegaly/gigantism; its population health impact remains unexplored. We measured R304* carrier frequency in 936 Mid Ulster, 1000 Greater Belfast (both in NI) and 2094 Republic of Ireland (ROI) volunteers and in 116 acromegaly/gigantism patients. Carrier frequencies were 0.0064 in Mid Ulster (95%CI=0.0027-0.013; p=0.0005 vs. ROI), 0.001 in Greater Belfast (0.00011-0.0047) and zero in ROI (0-0.0014). R304* prevalence was elevated in acromegaly/gigantism patients in NI (11/87,

12.6%, p<0.05), but not in ROI (2/29, 6.8%) vs. non-Irish patients (0-2.41%). Haploblock conservation supported a common ancestor for all the 18 identified Irish pedigrees (81 carriers, 30 affected). Time to most recent common ancestor (tMRCA) was 2550 (1275-5000) years. tMRCA-based simulations predicted 432 (90-5175) current carriers, including 86 affected (18-1035) for 20% penetrance. In conclusion, R304* is frequent in Mid Ulster, resulting in numerous acromegaly/gigantism cases. tMRCA is consistent with historical/folklore accounts of Irish giants. Forward simulations predict many undetected carriers; geographically-targeted population screening improves asymptomatic carrier identification, complementing clinical testing of patients/relatives. We generated disease awareness locally, necessary for early diagnosis and improved outcomes of *AIP*-related disease.

Keywords: *AIP*; acromegaly and gigantism; evolutionary genetics; founder mutation; population screening

Introduction

Germline aryl hydrocarbon receptor interacting-protein (*AIP*; MIM# 605555) mutations cause autosomal dominant familial isolated pituitary adenomas (FIPA) most commonly manifesting as acromegaly or gigantism. Due to incomplete penetrance, the disease can also manifest as apparently sporadic pituitary adenoma (PA) (Daly, et al., 2007; Leontiou, et al., 2008; Vierimaa, et al., 2006). These mostly GH- (somatotrophinomas) and/or prolactin-secreting tumours develop in 17-20% of *AIP* mutation (*AIP*mut) carriers, typically before 30 years of age (Beckers, et al., 2013; Hernández-Ramírez, et al., 2015). A diagnostic delay of several years from onset of symptoms is typical in somatotrophinomas, allowing tumour expansion and prolonged GH excess, leading to significant complications (Reddy, et al., 2010). Despite major therapeutical advances, management of somatotrophinomas remains challenging, especially in young patients with large/invasive tumours,

two frequent characteristics of *AIP*mut-positive patients (Beckers, et al., 2013). Identification of *AIP*mut carriers enables earlier clinical diagnosis and treatment, improving outcomes (Hernández-Ramírez, et al., 2015). To this end, predictive genetic testing of relatives of carriers is recommended (Korbonits, et al., 2012). General population screening is costly but targeted screening could be cost-effective when a disease-associated allele is geographically highly localised (Schiavi, et al., 2012), as might be expected for evolutionarily recent mutations. To date, population screening for genetic pituitary disease has not been performed.

We have previously inferred a recent origin for the NM_003977.3:c.910C>T (p.Arg304Ter) allele (p.R304* or R304*) in six FIPA pedigrees of Irish ancestry, including individuals born in the 18th and 20th centuries, in a small region within Mid Ulster, Northern Ireland (NI) (Chahal, et al., 2011; Stals, et al., 2011). Using the age estimate of R304*, we predicted through forward simulations a large number of current carriers (Chahal, et al., 2011). Therefore, we hypothesised that R304* would be frequent in the Irish general population, in particular in Mid Ulster, and should lead to a high proportion of R304*-positive patients with somatotrophinomas. In this study, we conducted a population screening in Mid Ulster, in comparison with two large population samples from Greater Belfast, NI and from the Republic of Ireland (ROI). In addition, we identified R304* carriers among patients with acromegaly/gigantism in two main Irish endocrine referral centres (Belfast and Dublin) and studied R304*-positive patients in our International FIPA Consortium database (Hernández-Ramírez, et al., 2015). We developed a new coalescent-based simulation approach to more precisely estimate the time to most recent common ancestor (tMRCA) of the Irish R304* allele based on haplotype data, and applied forward simulation to predict the number of carriers currently alive.

Materials and Methods

Subjects

We performed a cross-sectional genetic analysis study of general population adult individuals from three regions in Ireland: screening of volunteers from Mid Ulster (Local Government Districts of Magherafelt, Cookstown and Dungannon of NI) and genotyping of two large control groups from the Greater Belfast region – PRIME study participants (Linden, et al., 2012) – and the ROI Trinity Biobank (Table 1). Sample size calculations and screening procedures are described in the Supp. Methods.

A prospective cohort of unselected patients with acromegaly or gigantism were recruited at the University Hospital in Belfast, the only tertiary pituitary referral centre in NI (n=87, representing 60% of the NI Acromegaly Registry patients), and at the Beaumont Hospital, Dublin, the largest pituitary referral centre in ROI and closest to Mid Ulster (n=29). Additional R304*-positive pedigrees (5 Irish and 5 non-Irish) and 13 *AIP*mut-negative Irish FIPA pedigrees (Hernández-Ramírez, et al., 2015) were also included. Ethnicity – as assessed through family history – was unambiguous for all pedigrees. R304*-positive patients were previously reported (Chahal, et al., 2011; Hernández-Ramírez, et al., 2015; Igreja, et al., 2010; Leontiou, et al., 2008; Stals, et al., 2011; Williams, et al., 2014), while the other patients and subjects have not been previously described. Patients were tested for *AIP*muts, as previously described (Igreja, et al., 2010). The following pedigree codes were used: 'Sp' (sporadic), 'FIPA' (familial) and 'Screening' (screening-detected). Tooth-extracted DNA from a pituitary giant's skeleton at Trinity College Dublin (Cunningham, 1892) was sequenced for *AIP*mut, as previously described (Chahal, et al., 2011). The study protocol was approved by the local Ethics Committees; all study participants gave written informed consent.

Evolutionary Genetics and Statistical Analysis

Fourteen microsatellites (STR) covering 8.3 Mbp around the *AIP* gene were genotyped in a minimum of one R304* carrier per pedigree, as previously described (Chahal, et al., 2011). Haplotypes were computed using PHASE (Stephens, et al., 2001), incorporating phasing information deduced from genotypes of closely-related carriers (three pedigrees) (Supp. Table S1). To estimate the tMRCA of R304*-containing haplotypes, we developed a novel inference methodology combining an analytical result from coalescence theory and simulations in an Approximate Bayesian Computation framework (Beaumont, et al., 2002). First, we computed the tMRCA based on a smaller haplotype block around R304* that was fully conserved in 18 Irish pedigrees (Supp. Table S2, row E). The full conservation allowed us to apply an analytical formula (Donnelly, et al., 1996). The tMRCA distribution resulting from this first step became the prior distribution for the second step which used a simulation-based approach to incorporate additional conservation data of haploblocks shared only between subsets of pedigrees. We simulated genealogies with recombination and mutation using the program *ms* (Hudson, 2002) (Supp. Figure S1) and generated distributions of tMRCA from those simulations that were closest to the recombination and mutation pattern inferred from our haplotype data (Supp. Figure S2). Results were based on sex-averaged genetic distances for *AIP* and microsatellite loci, from HapMap v2 (The HapMap International Consortium, 2007) and Rutgers v3 (Matise, et al., 2007) genetic maps (Supp. Table S1). Next, starting with tMRCAs randomly chosen from the simulated tMRCA distribution (Supp. Figure S3*A, B*), we took a forward simulation approach to generate possible trajectories for the allele frequency in the population, through binomial sampling. This resulted in distributions of the expected present-day number of carriers, which we conditioned to have at least the minimum number of R304* carriers/generation observed in our dataset (n=27) (Supp. Figure S3*C, D*). Detailed procedures, including statistical analysis are described as Supp. Methods.

Results

Population Screening Reveals a Significantly High Carrier Frequency of the R304* Allele in Northern Ireland

Several families of patients suffering from acromegaly or gigantism and carrying the Irish R304* allele came from a small geographical area within Mid Ulster in NI (Chahal, et al., 2011; Stals, et al., 2011). In order to estimate the local carrier frequency of R304*, we screened a population sample of 936 adults (Table 1), 90% of which lived in Mid Ulster.

We identified six R304* heterozygous individuals (Supp. Table S3), corresponding to a carrier frequency estimate of 0.0064 (95% probability interval [CI]: 0.0027-0.013). Two related carriers, negative for personal or family history of PA, represented a novel R304* pedigree (Screening 1) (Supp. Tables S3 and S4). The remaining carriers detected through screening were two patients previously diagnosed with somatotrophinomas (pedigrees Sp 4 and FIPA 4) and two unaffected carriers from previously identified R304*-positive pedigrees Sp 4 and FIPA 1 (Supp. Tables S3 and S4). The R304* carrier status was significantly associated with a personal diagnosis of PA ($p<0.001$, Fisher's exact test) and with a family history of PA (FIPA or sporadic, $p<0.001$, Fisher's exact test). Mid Ulster screening revealed many other PA patients, either directly (R304*-negative PA patients participating to screening) or indirectly (non-participating PA patients mentioned as family history of R304*-negative screening subjects) (Supp. Table S3).

The Greater Belfast control population sample (n=1000, Table 1) revealed one R304*-positive individual; corresponding to a carrier frequency of 0.001 (95% CI: 0.00011-0.0047).The carrier was unaffected (clinical examination, hormonal measurements and pituitary imaging), did not have a family history of PA, and cascade testing of relatives revealed two carriers, both unaffected (Supp. Table S4, Screening 2 pedigree).

In the ROI control population sample (n=2094, Table 1), no R304*-positive individuals were identified, corresponding to zero carrier frequency (95% CI estimate 0-0.0014). This is in accord with the absence/extremely low R304* carrier frequency observed in diverse population samples included in the Exome Aggregation Consortium (http://exac.broadinstitute.org/): two heterozygotes in 34,856 Europeans (0.000057) and none in 23,450 non-Europeans. The Mid Ulster carrier frequency was significantly higher than the ROI one (p=0.0005, Fisher's exact test), while the Greater Belfast one did not differ from either ROI or Mid Ulster.

Extrapolation of our NI R304* carrier frequency estimates (1/1000 and 6/936) and 95% CIs to the population of Greater Belfast (579,276) and Mid Ulster (139,011), comprising 40% of NI, according to the 2011 census (http://www.ninis2.nisra.gov.uk), yielded an estimated number of carriers of 1470 (95% CI: 439-4530).

R304* is Common in Irish Patients with Acromegaly/Gigantism

In order to characterise the extent of R304*-related pituitary disease in Ireland, we tested for *AIP* alleles in 116 patients with acromegaly/gigantism from the two tertiary endocrine centres close to Mid Ulster. We identified 11 (12.6%) R304*-positive patients with somatotrophinomas in the NI Acromegaly Registry, Belfast, and two (6.8%) in the Dublin centre patients, while five NI (5.7%) and two Dublin patients (6.8%) presented other *AIP* variants (Supp. Table S5).

The R304*-positive patients belonged to pedigrees FIPA 1-5 and Sp 1-6 (Supp. Table S4). The R304* prevalence among NI patients with somatotrophinomas was higher than that of large non-Irish somatotrophinoma series (Cazabat, et al., 2012; Preda, et al., 2014; Schöfl, et al., 2014; Tichomirowa, et al., 2011) (0-2.41%; p<0.05, Fisher's exact test). Geographically, R304*-positive patients with somatotrophinomas predominated in Mid Ulster, where they, remarkably, outnumbered *AIP*mut-negative patients (Figure 1).

Irish R304*-positive patients with somatotrophinomas (excluding those diagnosed prospectively, following predictive genetic testing) displayed the known features of *AIP*mut-positive PAs: younger age at disease onset/ diagnosis, larger pituitary tumours, increased frequency of gigantism and familial disease, compared to *AIP*mut-negative patients (Table 2).

Our investigations revealed, however, a wider range of phenotypes. While two patients, diagnosed as part of cascade testing in families, harboured macroadenomas and underwent surgery, two prospectively diagnosed R304*-positive patients had pituitary microadenomas and four patients had disease onset after the age of 30 years (Hernández-Ramírez, et al., 2015). Interestingly, none of the patients carrying other *AIP* variants presented a PA family history.

All Irish R304* Pedigrees Share a Common Ancestor That Lived Approximately 2500 Years Ago

Having identified 13 R304*-positive pedigrees through population screening and testing of somatotrophinoma patients in Ireland, we searched the International FIPA Consortium database for additional R304*-positive pedigrees and identified 10 more, resulting in a total of 23 R304*-positive pedigrees (Figure 2). These 10 additional pedigrees were of diverse ethnic backgrounds: six from the UK: one of English and five of Irish ancestry (FIPA 6-8, Sp 7 and 18th century patient pedigrees) and four from other countries (Figure 2 and Supp. Table S4). In this database, we also identified 13 *AIP*mut-negative Irish FIPA pedigrees (Supp. Table S6).

By reconstructing *AIP* gene region STR haplotypes in these 23 pedigrees, we determined that 18 of them shared a 0.2-1.95 Mbp fully conserved haploblock around R304*, as well as extended haploblocks covering up to the entire 8.3 Mbp genotyped region (Figure 2 and Supp. Table S1). These data support the existence of a recent common ancestral carrier haplotype, the Irish R304* founder. Fourteen of these 18 pedigrees were living in Ireland and the other four had known Irish ancestry. The five non-Irish pedigrees did not share significant haploblocks with the Irish ones or among each other (Figure 2), supporting the existence of recurrent independent R304* mutation

events at this mutation-prone CpG dinucleotide (Cazabat, et al., 2012; Chahal, et al., 2011; Cuny, et al., 2013; Daly, et al., 2007; de Lima, et al., 2012; Leontiou, et al., 2008; Niyazoglu, et al., 2014; Occhi, et al., 2010; Tichomirowa, et al., 2011; Vierimaa, et al., 2006).

The total number of Irish allele carriers was 90 (37 affected, 53 unaffected), 81 of which are currently alive (30 affected, 51 unaffected). Seven of the 51 unaffected living carriers (13.7%) were detected exclusively by population screening. The highest geographical concentration of R304* carriers in Ireland was observed in Mid Ulster, both for affected (somatotrophinoma) and unaffected individuals (Figure 1), corresponding to eight different pedigrees. A third of the Irish allele carriers (32%, 26/81) lived outside of Ireland: in England (21), Scotland (2), Australia (2) and Canada (1).

To estimate the time to the most recent common ancestor (tMRCA) of the R304* carrier haplotypes among the Irish pedigrees, we developed a novel coalescent-based approach, combining analytical calculations with haplotype simulation in an Approximate Bayesian Computation (Beaumont, et al., 2002) framework (Supp. Methods). The tMRCA estimates of the Irish R304* haplotypes were 102 (51-200) generations - median (95% CI) - based on HapMap, and 101 (50-179) generations, based on Rutgers map genetic distances (Supp. Figure S3*A, B*). These tMRCA distributions, e.g. 51-200 generations (HapMap-based) overlap substantially with those previously estimated: 17-150 generations (Chahal, et al., 2011) (Pr(X>Y) = 0.79). Assuming a generation time of 25 years (Chahal, et al., 2011), current estimates translate to 2550 (1275-5000) years (HapMap) and 2525 (1250-4475) years (Rutgers). To estimate the number of living subjects carrying the Irish R304* allele, forward simulations conditioned on the number of observed carriers predicted 144 (30-1725) and 141 (30-1430) carriers per generation - median (95% CI) - based on HapMap and Rutgers distances, respectively (Supp. Figure S3*C, D*). For three overlapping generations alive at present, we estimate the current number of carriers as 3 × 144 = 432 (90-5175; HapMap-based), corresponding to 86 (18-1035) pituitary adenoma patients, assuming 20% penetrance (Beckers, et al., 2013).

Historical Irish Giants

The medical literature, as well as Irish folklore, holds numerous descriptions of Irish giants. For some of these presumed pituitary gigantism individuals there is historical and medical evidence for the diagnosis (Supp. Table S7). We have tested DNA samples from two historical giants for *AIP* derived alleles: Charles Byrne (1761-1783), born in Mid Ulster, who carried the Irish R304* allele (Chahal, et al., 2011) and Cornelius Magrath (1736-1760), born in the Southern coast of Ireland and whose skeleton is conserved at Trinity College, Dublin (Cunningham, 1892), who was R304*-negative. Five additional giants related to known R304* carriers were presumed R304*-positive: Subjects 6, 7, 11, 13 and 19 (Supp. Table S7). Two unrelated Mid Ulster screening participants, R304*-negative themselves, provided photographic evidence of their extremely tall relatives, whom we included as historical Irish giants (Figure 3 and Supp. Table S7).

Discussion

In this study we demonstrated that the R304* *AIP* allele is present in the general population of Ireland and its frequency varies geographically, from a high of 6/936 in Mid Ulster to 1/1000 in the Greater Belfast region (both in NI), while absent in a ROI population sample. These differences were paralleled by the geographical distribution of R304*-positive somatotrophinoma cases, representing a significantly higher proportion of the somatotrophinoma patient population in NI (12.6%), than in large published somatotrophinoma cohorts (maximum 2.41%) (Cazabat, et al., 2012; Preda, et al., 2014; Schöfl, et al., 2014; Tichomirowa, et al., 2011), while in the ROI (Dublin centre) this proportion was intermediate (6.8%). Furthermore, the number of R304* carriers, both patients with somatotrophinomas and unaffected carriers, was highest in Mid Ulster. These data strongly support our hypothesis that Mid Ulster has an elevated R304* carrier frequency. However, 32% of the Irish

R304* allele carriers were identified outside of Ireland, an observation attributable to emigration. Another consequence of the increased R304* carrier frequency in Ireland is that a large proportion (8 out of 21, 38%) of Irish FIPA families are due to R304* - the only *AIP*mut identified in Irish FIPA so far.

We demonstrate that all 18 R304*-positive pedigrees of Irish origin identified in the study inherited this allele from a common ancestor, the R304*founder. In addition, we have shown that R304* in pedigrees of English, Indian, Romanian, US Italian, Irish and Mexican origin derives from independent recurrent mutational events (Chahal, et al., 2011; Ramirez-Renteria, et al., 2016). Founder *AIP*mut alleles have also been identified through haplotype analysis in Finnish (Vierimaa, et al., 2006), Italian (Occhi, et al., 2010), Comoros (Cuny, et al., 2013) and English (Salvatori, et al., 2014) populations, involving the p.Q14*, p.R304*, p.G117Afs*39, and p.F269_H275dup alleles, respectively, but the present population frequency of all these founder alleles remains unknown.

The refined coalescent simulation-based Approximate Bayesian Computation approach we describe in this paper provides a practical framework applicable to the estimation of tMRCA of identity-by-descent alleles. Previous estimates using five pedigrees and a simpler approach indicated a more recent common ancestor (66 generations, 95% CI=17-150) (Chahal, et al., 2011), although the difference between new and previous estimates was not statistically significant (Pr(X>Y) = 0.79). Although the founder probably lived around 2500 years ago, many of today's carriers are concentrated in a small region, suggesting a limited local migratory activity, despite significant emigration in recent centuries. A population bottleneck followed by re-expansion may explain the Mid Ulster R304* cluster, although genetic drift in a constant sized or growing population is consistent with observed frequencies and estimated age of this allele. Persistence of the R304* allele in this population may suggest the absence of, or only weak, purifying selection acting on this locus. While R304*-associated disease manifestations include hypopituitarism, infertility and shortened life-span, low disease penetrance will lead to a reduced selective disadvantage.

Additionally, it is possible that there were inclusive fitness effects in the unaffected carrier relatives of giants in the past – perhaps as a result of elevated status – that may have counterbalanced selective disadvantages in affected carriers.

Identification of asymptomatic *AIP*mut carriers enables prospective early diagnosis of PAs, followed by prompt and effective treatment, with improved chances of curing the disease and preventing complications (Hernández-Ramírez, et al., 2015; Williams, et al., 2014). To this end, cascade testing of *AIP*mut-positive patient relatives is recommended; however, limited knowledge of family relations, non-disclosure of information between relatives and non-acceptance of testing may hinder these efforts. While carrier identification in affected individuals is now becoming standard, detection of unaffected carriers and their endocrine screening is a challenge for the future. Supported by substantial patient and community involvement, and by local media coverage, our study has created awareness about *AIP*-related disease in Ireland, a necessary precursor for improved disease recognition and acceptance of genetic testing. Although population screening is an unbiased approach to carrier identification and could detect unaffected carriers without family history of pituitary disease, further studies are needed to justify this approach. Our study provides a proof-of-principle that asymptomatic R304* carriers in Ireland can be identified through population screening, by identifying two novel R304*-positive pedigrees comprising a relatively large proportion (7/52, 13.5%) of the known number of living unaffected carriers.

Given the tMRCA-predicted number of Irish R304* carriers (432, 95% CI: 90-5175, 86 affected expected at 20% penetrance) and that of known living carriers (81, of which 30 affected), we estimate the number of undetected carriers as the difference between predicted and known carriers, resulting in around 351 undetected carriers, including 56 affected patients. Many of these undetected carriers may actually live outside of Ireland, in countries with significant Irish immigration, such as Great Britain, Canada and Australia, where 32% of the known living Irish allele carriers reside, and the USA, where *AIP* mutation testing has been limited to date. For NI, alternative

calculations by extrapolating population carrier frequency estimates (Mid Ulster and Greater Belfast) to regional population size (approximately 40% of NI), estimated 340 to 5138 undetected carriers, a range comparable to the tMRCA-predicted estimate.

Several key features contribute to our study's results and impact: 1) patient and general public involvement in its design and conduct, 2) analysis of multiple Irish general population samples and of a large unbiased patient cohort - the NI Acromegaly Registry, 3) analysis of the largest R304* pedigree collection to date, thanks to international collaboration, and 4) the incorporation of historical and ancient DNA data into our analyses. In comparison, studies describing other *AIP*mut founder alleles, as well as our own previous study of the Irish R304* allele, examined limited numbers of *AIP*mut pedigrees and relatively small numbers of patients and population controls, without providing estimates of population carrier frequencies of these alleles and their geographical distribution (Chahal, et al., 2011; Cuny, et al., 2013; Occhi, et al., 2010; Salvatori, et al., 2014; Vierimaa, et al., 2006).

Our study also has limitations. For practical reasons, only three large Irish general population samples were screened for R304*. Regarding PA types included in the study, we chose to include only patients with somatotrophinomas, as this is largely the commonest PA type in *AIP*mut carriers and the only one for which population-level data was available. Patients with prolactinomas can also harbour *AIP* mutations, although significantly less frequently than somatotrophinomas (Cazabat, et al., 2012; Cuny, et al., 2013; Preda, et al., 2014; Tichomirowa, et al., 2011); the frequency of R304* in Irish patients with prolactinomas remains to be determined. Sampling of patients with somatotrophinomas from ROI was limited to the Dublin centre, based on its proximity to Mid Ulster, and fewer patients were analysed, compared to NI. Future studies will help to better characterise the R304* carrier frequency in the ROI general and PA patient populations. Not all living members of R304*-positive pedigrees were available for genetic and clinical testing; this is a common difficulty in genetic studies and clinical practice. Our evolutionary genetics approach compensated for this, by

estimating the number of undetected allele carriers. Overall, we believe that these limitations have relatively little effect on our conclusions.

Our work suggested several measures to address the challenging task of identifying the large number of undetected Irish R304* allele carriers, in order to improve the outcomes of PA patients. 1) We propose R304* testing of patients of Irish descent with somatotrophinomas, especially ones with younger (< 30 years of age) onset, in Ireland and abroad, particularly in the Great Britain, USA, Canada and Australia, where large Irish immigrant populations exist. 2) Working closely together with patients and their communities has improved knowledge about *AIP*-related disease, which may lead to earlier recognition of disease, and hopefully increased acceptance of genetic testing. 3) Population screening in Ireland, especially in Mid Ulster, might be effective, but more study is needed regarding the psychological and economic implications, as well as further data on the clinical benefits of R304* screening (Hernández-Ramírez, et al., 2015).

Our results open the way for future studies of several key aspects of *AIP*-related disease. The Irish R304* cohort is unique in having a large number of carriers sharing the same pathogenic gene alteration and promoter area within the fully conserved haploblock, yet pedigrees display differences in penetrance and patient phenotypes differ significantly. Currently, it is not known what influences disease penetrance in *AIP*mut-positive individuals. Different individual *AIP*mut alleles (Igreja, et al., 2010) or classes (e.g. truncating vs. non-truncating) (Hernández-Ramírez, et al., 2015), changes in gene expression regulation (Cooper, et al., 2013) and other epistatic interactions may each play a role, as will other genetic and environmental factors. Further genetic studies of this cohort could help the identification of pituitary disease-modifying genes. Follow-up of clinically-identified and screening-detected pedigrees will provide new data about the natural history of disease in carriers, optimal follow-up schedules, efficiency and outcome of population screening.

Irish folklore has numerous stories regarding Irish giants and the remains of some of these giants have been studied in the past (Chahal, et al., 2011; Cunningham, 1892; Frankcom and Musgrave, 1976). Our data provides an explanation for the observation made by the pioneering anthropologist James C. Prichard in 1826: *In Ireland men of uncommon stature are often seen, and even a gigantic form and stature occur there much more frequently than in this island [Britain]… We can hardly avoid the conclusion that there must be some peculiarity in Ireland which gives rise to these phenomena (Prichard, 1826).*

Supporting information

Supp. Methods, Supp. Figures S1-S3, Supp. Tables S1-S7 and references (Austerlitz, et al., 2003; Bergland, 1965; Burger, et al., 2007; Carleton, 1996; Colombo, 2007; Fawcett, 1909; Frankcom and Musgrave, 1976; Georgitsi, et al., 2007; Lin, et al., 2007; Lynass, 1842; Oriola, et al., 2013; Prezio, et al., 1961; Raitila, et al., 2010; Stephens, et al., 1998; Templeton, 2006; Trivellin, et al., 2014) can be found in the online version of this article under "Supporting Information".

Acknowledgements

Conflict of interest:

MK received grant funding from Novartis and Pfizer and is a member of Medical Advisory Board of Pfizer Inc. All the other authors have nothing to declare.

References

Austerlitz F, Kalaydjieva L, Heyer E. 2003. Detecting population growth, selection and inherited fertility from haplotypic data in humans. Genetics 165(3):1579-86.

Beaumont MA, Zhang W, Balding DJ. 2002. Approximate Bayesian computation in population genetics. Genetics 162(4):2025-2035.

Beckers A, Aaltonen LA, Daly AF, Karhu A. 2013. Familial isolated pituitary adenomas (FIPA) and the pituitary adenoma predisposition due to mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. Endocr Rev 34(2):239-77.

Bergland RM. 1965. New information concerning the Irish giant. J Neurosurg 23(3):265-9.

Burger J, Kirchner M, Bramanti B, Haak W, Thomas MG. 2007. Absence of the lactase-persistence-associated allele in early Neolithic Europeans. Proc Natl Acad Sci U S A 104:3736-3741.

Carleton W. 1996. William Carleton: the Autobiography: White Row Press Ltd.

Cazabat L, Bouligand J, Salenave S, Bernier M, Gaillard S, Parker F, Young J, Guiochon-Mantel A, Chanson P. 2012. Germline AIP mutations in apparently sporadic pituitary adenomas: Prevalence in a prospective single-center cohort of 443 patients. J Clin Endocrinol Metab 97(April):1-8.

Chahal HS, Stals K, Unterländer M, Balding DJ, Thomas MG, Kumar AV, Besser MG, Atkinson BA, Morrison PJ, Howlett TA, Levy MJ, Orme SM, et al. 2011. AIP mutation in pituitary adenomas in the 18th century and today. N Engl J Med 364(1):43-50.

Colombo R. 2007. Dating Mutations. eLS: John Wiley & Sons, Ltd.

Cooper DN, Krawczak M, Polychronakos C, Tyler-Smith C, Kehrer-Sawatzki H. 2013. Where genotype is not predictive of phenotype: Towards an understanding of the molecular basis of reduced penetrance in human inherited disease. Hum Genet 132(10):1077-1130.

Cunningham DJ. 1892. The skull and some of the other bones of the skeleton of Cornelius Magrath, the Irish giant. The Journal of the Anthropological Institute of Great Britain and Ireland 21:40-41.

Cuny T, Pertuit M, Sahnoun-Fathallah M, Daly A, Occhi G, Odou MF, Tabarin A, Nunes ML, Delemer B, Rohmer V, Desailloud R, Kerlan V, et al. 2013. Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don't forget MEN1 genetic analysis. Eur J Endocrinol 168(4):533-41.

Daly AF, Vanbellinghen J-F, Khoo SK, Jaffrain-Rea M-L, Naves LA, Guitelman MA, Murat A, Emy P, Gimenez-Roqueplo A-P, Tamburrano G, Raverot G, Barlier A, et al. 2007. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 92(5):1891-6.

de Lima DS, Martins CS, Paixao BMDC, Amaral FC, Colli LM, Saggioro FP, Neder L, Machado HR, dos Santos ARD, Pinheiro DG, Moreira AC, Silva WA, et al. 2012. SAGE analysis highlights the putative role of underexpression of ribosomal proteins in GH-secreting pituitary adenomas. Eur J Endocrinol 167(6):759-68.

Donnelly P, Tavaré S, Balding DJ, Griffiths RC. 1996. Estimating the age of the common ancestor of men from the ZFY intron. Science 272(5266):1357-9; author reply 1361-2.

Fawcett E. 1909. Patrick Cotter-The Bristol Giant. The Journal of the Royal Anthropological Institute of Great Britain and Ireland 39(Jan-Jun 1909):196-208.

Frankcom G, Musgrave JH. 1976. The Irish Giant: Gerald Duckworth & Co Ltd.

Georgitsi M, Raitila A, Karhu A, Tuppurainen K, Mäkinen MJ, Vierimaa O, Paschke R, Saeger W, van der Luijt RB, Sane T, Robledo M, De Menis E, et al. 2007. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc Natl Acad Sci U S A 104(10):4101-5.

Hernández-Ramírez LC, Gabrovska P, Dénes J, Stals K, Trivellin G, Tilley D, Ferrau F, Evanson J, Ellard S, Grossman AB. 2015. Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis in AIP Mutation Carriers. J Clin Endocrinol Metab 100(9):E1242-54.

Hudson RR. 2002. Generating samples under a Wright-Fisher neutral model of genetic variation. Bioinformatics (Oxford, England) 18:337-338.

Igreja S, Chahal HS, King P, Bolger GB, Srirangalingam U, Guasti L, Chapple JP, Trivellin G, Gueorguiev M, Guegan K, Stals K, Khoo B, et al. 2010. Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families. Hum Mutat 31(8):950-60.

Korbonits M, Storr H, Kumar AV. 2012. Familial pituitary adenomas - who should be tested for AIP mutations? Clin Endocrinol (Oxf) 77(3):351-6.

Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J, Stolbrink M, Christian HC, et al. 2008. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J Clin Endocrinol Metab 93(6):2390-401.

Lin BC, Sullivan R, Lee Y, Moran S, Glover E, Bradfield CA. 2007. Deletion of the aryl hydrocarbon receptor-associated protein 9 leads to cardiac malformation and embryonic lethality. The Journal of Biological Chemistry 282(49):35924-32.

Linden GJ, Linden K, Yarnell J, Evans A, Kee F, Patterson CC. 2012. All-cause mortality and periodontitis in 60-70-year-old men: a prospective cohort study. J Clin Periodontol 39(10):940-6.

Lynass B. 1842. Orange & Love Poems and Songs. Belfast.

Matise TC, Chen F, Chen W, De La Vega FM, Hansen M, He C, Hyland FCL, Kennedy GC, Kong X, Murray SS, Ziegle JS, Stewart WCL, et al. 2007. A second-generation combined linkage-physical map of the human genome. Genome Res 17:1783-1786.

Niyazoglu M, Sayitoglu M, Firtina S, Hatipoglu E, Gazioglu N, Kadioglu P. 2014. Familial acromegaly due to aryl hydrocarbon receptor-interacting protein (AIP) gene mutation in a Turkish cohort. Pituitary 17(3):220-6.

Occhi G, Jaffrain-Rea ML, Trivellin G, Albiger N, Ceccato F, De Menis E, Angelini M, Ferasin S, Beckers A, Mantero F, Scaroni C. 2010. The R304X mutation of the aryl hydrocarbon receptor interacting protein gene in familial isolated pituitary adenomas: Mutational hot-spot or founder effect? J Endocrinol Invest 33(11):800-5.

Oriola J, Lucas T, Halperin I, Mora M, Perales MJ, Alvarez-Escolá C, Paz DM-N, Díaz Soto G, Salinas I, Julián MT, Olaizola I, Bernabeu I, et al. 2013. Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues. Eur J Endocrinol 168(1):9-13.

Preda V, Korbonits M, Cudlip S, Karavitaki N, Grossman AB. 2014. Low rate of germline AIP mutations in patients with apparently sporadic pituitary adenomas before the age of 40: a single-centre adult cohort. Eur J Endocrinol 171(5):659-66.

Prezio JA, Griffin JE, O'Brien JJ. 1961. Acromegalic gigantism. The Buffalo giant. The American Journal of Medicine 31:966-76.

Prichard JC. 1826. Researches into the physical history of mankind. London: Printed for John and Arthur Arch, Cornhill.

Raitila A, Lehtonen HJ, Arola J, Heliövaara E, Ahlsten M, Georgitsi M, Jalanko A, Paetau A, Aaltonen LA, Karhu A. 2010. Mice with inactivation of aryl hydrocarbon receptor-interacting protein (Aip) display complete penetrance of pituitary adenomas with aberrant ARNT expression. The American Journal of Pathology 177(4):1969-76.

Ramirez-Renteria C, Hernandez-Ramirez LC, Portocarrero-Ortiz L, Vargas G, Melgar V, Espinosa E, Espinosa-de-Los-Monteros AL, Sosa E, Gonzalez B, Zuniga S, Unterlander M, Burger J, et al. 2016. AIP mutations in young patients with acromegaly and the Tampico Giant: the Mexican experience. Endocrine.

Reddy R, Hope S, Wass J. 2010. Acromegaly. BMJ 341:c4189-c4189.

Salvatori R, Gabrovska P, Weber A, Quinton R, Crowne EC, Corrazzini V, Radian S, Sinha K, Lecoq A-L, Chanson P, Thomas MG, Baborie A, et al. Founder effect in recurring AIP mutation causing familial isolated pituitary adenoma syndrome. Endocrine Society's 96th Annual Meeting and Expo, June 21–24, 2014 – Chicago. Endocrine Reviews Supplement: ENDO 2014 Abstracts: p SUN-0698 (Abstract)

Schiavi F, Demattè S, Cecchini ME, Taschin E, Bobisse S, Del Piano A, Donner D, Barbareschi M, Manera V, Zovato S, Erlic Z, Savvoukidis T, et al. 2012. The endemic paraganglioma syndrome type 1: origin, spread, and clinical expression. J Clin Endocrinol Metab 97(4):E637-41.

Schöfl C, Honegger J, Droste M, Grussendorf M, Finke R, Plöckinger U, Berg C, Willenberg HS,
Lammert A, Klingmüller D, Jaursch-Hancke C, Tönjes A, et al. 2014. Frequency of AIP gene
mutations in young patients with acromegaly: a registry-based study. J Clin Endocrinol
Metab 99(December):E2789-93.

Stals K, Trivellin G, Korbonits M. 2011. AIP mutation in pituitary adenomas. N Engl J Med
364(20):1974-5.

Stephens JC, Reich DE, Goldstein DB, Shin HD, Smith MW, Carrington M, Winkler C, Huttley GA,
Allikmets R, Schriml L, Gerrard B, Malasky M, et al. 1998. Dating the origin of the CCR5-
Delta32 AIDS-resistance allele by the coalescence of haplotypes. Am J Hum Genet
62(6):1507-15.

Stephens M, Smith NJ, Donnelly P. 2001. A new statistical method for haplotype reconstruction from
population data. Am J Hum Genet 68(4):978-89.

Templeton AR. 2006. Population Genetics And Microevolutionary Theory. Hoboken, New Jersey:
John Wiley & Sons, Inc.

The International HapMap Consortium. 2007. A second generation human haplotype map of over
3.1 million SNPs. Nature 449:851-61.

Tichomirowa MA, Barlier A, Daly AF, Jaffrain-Rea ML, Ronchi C, Yaneva M, Urban JD, Petrossians P,
Elenkova A, Tabarin A, Desailloud R, Maiter D, et al. 2011. High prevalence of AIP gene
mutations following focused screening in young patients with sporadic pituitary
macroadenomas. Eur J Endocrinol 165:509-515.

Trivellin G, Daly AF, Faucz FR, Yuan B, Rostomyan L, Larco DO, Schernthaner-Reiter MH, Szarek E,
Leal LF, Caberg J-H, Castermans E, Villa C, et al. 2014. Gigantism and acromegaly due to Xq26
microduplications and GPR101 mutation. N Engl J Med:1-12.

Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TML,

Salmela PI, Paschke R, Gündogdu S, De Menis E, et al. 2006. Pituitary adenoma

predisposition caused by germline mutations in the AIP gene. Science 312(5777):1228-30.

Williams F, Hunter S, Bradley L, Chahal HS, Storr HL, Akker SA, Kumar AV, Orme SM, Evanson J, Abid

N, Morrison PJ, Korbonits M, et al. 2014. Clinical experience in the screening and

management of a large kindred with familial isolated pituitary adenoma due to an aryl

hydrocarbon receptor interacting protein (AIP) mutation. J Clin Endocrinol Metab

99(4):1122-31.

Figure legends

Figure 1 Geographical distribution of R304* allele carriers in Ireland, compared to *AIP*mut-negative patients with somatotrophinomas. R304* carriers, unaffected (R304* unaffected, green columns) and patients with somatotrophinomas (R304* GH, red columns) were compared to *AIP*mut-negative patients with somatotrophinomas (*AIP*-neg GH, blue columns). Only subjects currently residing in Ireland were included; R304*-positive patients with other PA types (n=5) are not shown. The map was arbitrarily divided into regions separated by dotted borders, red for Mid Ulster. Ninety percent of the Mid Ulster screening subjects resided here, including all six R304* carriers. Each small graph summarizes data from the underlying region; the y-axis scale is identical for all graphs.

Figure 2 Microsatellite haplotypes of chromosome 11q12.2-13.3 of R304*-positive pedigrees. Irish (first two rows) and non-Irish pedigrees (third row) are shown. Marker alleles are displayed as amplicon sizes. Dark shading: haploblock shared between all Irish pedigrees (0.2-1.95 Mbp long); light shading: additional shared haploblocks. Thick horizontal lines represent *AIP* alleles (black = wild-type, yellow = R304*); intervals between markers are not drawn to scale. Sp = sporadic PA. Haplotypes of 18th century patient, FIPA 1, 2, 3, 6, 7, FIPA UK, Romania, US (Italian) and Sp India pedigrees have been previously published (Chahal, et al., 2011; Stals, et al., 2011).

Figure 3 New evidence of historical Irish giants. (A) Subject 15 (Supp. Table S7), 211cm tall, from Maghera, Mid Ulster, uncle of a screening participant, died of a hypertensive crisis one month after photograph was taken - 13th May 1918, Daily Sketch (Canadian newspaper). (B) Group of Irish immigrants from Garvagh (a town close to Mid Ulster) after arrival in Western Australia, 1910. At centre with the pole, Subject 16 (Supp. Table S7), 213 cm tall; standing far left - unrelated subject with pronounced acromegalic features and tall stature (photograph from Garvagh Museum, NI).

Table Captions

Table 1. Demographic parameters of Irish population samples.

	Mid Ulster (n=936)	Greater Belfast (n=1000)	ROI (n=2094)	
Sample type	Saliva DNA	Blood DNA	Blood DNA (n=1095)	Buccal swab DNA (n=999)
Males - count (proportion)	435 (46.5%)	1000 (100%)	486 (44.4%)	559 (55.9%)
Age - years, median (range)	46 (18-85)	64 (58-72)	37 (19-69)	53 (18-76)
R304* / wt *AIP* genotype	6	1[a]	0	0
wt/wt *AIP* genotype	930	999	1095	999
R304* carrier frequency	6/936	1/1000	0	0

[a] 71 years old male, normal height, no clinical signs of pituitary disease, normal serum hormone levels (basal IGF-I, prolactin, and GH serum levels during the oral glucose tolerance test (GH-OGTT)), normal pituitary MRI examination - subsequently died of a pulmonary mesothelioma linked to asbestos exposure, aged 72 years; cascade testing of relatives (Screening 2 pedigree) identified two unaffected R304* carriers: 1M, 77 years, clinically unaffected and 1F, 42 years, clinically unaffected, normal pituitary MRI, random GH=4.7 ng/mL, minimal IGF-I increase (1·07 x ULN), normal PRL, GH-OGTT not yet performed. wt, wild-type

Table 2. Clinical characteristics of Irish R304*-positive somatotrophinoma patients (NI Acromegaly

Registry, Dublin patients and FIPA Consortium database) compared to *AIP*mut-negative Irish patients

with somatotrophinomas (NI and Dublin patients).

AIP genotype	Heterozygous NM_003977.3:c.910C>T	Homozygous wild-type	*p* value
	n=31	n=96	
Median age (range) at onset (years)	17 (6-68) (n=29)	38.5 (14-85) (n=64)	<0.0001
Median age (range) at diagnosis (years)	19.5 (7-68) (n=30)	46 (19-85) (n=95)	<0.0001
Age <30 years at disease onset	27/31 (87.1 %)	21/96 (21.9 %)	<0.0001
Mean tumour size (mm)	23.8 ± 10.6 (n=11)	17.2 ± 8.4 (n=43)	<0.05
Pituitary macroadenoma	22/24 (91.7 %)	58/70 (82.9 %)	ns
Gigantism	18/31 (58.1 %)	7/96 (7.3 %)	<0.0001
Family history of PA	24/31 (77.4 %)	3/94 (3.2 %)	<0.0001

ns = not significant

18th century patient, FIPA 1–8

Marker	18th century patient		FIPA 1		FIPA 2		FIPA 3		FIPA 4		FIPA 5		FIPA 6		FIPA 7		FIPA 8	
D11S4076			80	86	80	80	88	84	90	90	86	88	88	92	80	80	88	88
D11S4205			197	193	197	193	193	193	197	195	193	193	197	193	197	193	193	189
D11S1883	104	106	116	104	116	108	108	112	116	120	102	104	108	110	116	108	106	114
Chr11-64-AC-110	95	101	105	105	105	99	105	103	105	95	105	101	105	103	105	103	101	103
Chr11-64-TG-110	103	101	103	85	103	107	111	113	103	107	103	105	103	105	103	97	103	85
D11S913	99	99	99	99	99	99	99	97	99	97	99	101	99	99	99	101	99	97
D11S1249			114	116	114	110	114	118	114	112	114	112	114	112	114	112	114	108
D11S1889	118	126	118	124	118	108	118	126	118	120	118	124	118	126	118	124	118	126
D11S987	97	103	97	111	97	103	97	103	103	99	103	105	97	107	97	99	97	105
Chr11-67-TG-107	101	103	103	97	101	103	101	105	101	105	101	103	101	109	101	103	101	103
D11S1337			282	282	290	282	290	280	290	282	282	284	290	284	290	282	290	282
D11S4178			248	248	248	248	248	238	248	250	248	248	248	254	248	248	248	248
D11S4095			102	102	108	102	108	102	108	108	108	102	108	102	108	108	98	112
D11S4136			102	110	112	108	112	120	110	110	112	112	112	112	112	112	104	112

Sp 1–7, Screening 1, Screening 2

Marker	Sp 1		Sp 2		Sp 3		Sp 4		Sp 5		Sp 6		Sp 7		Screening 1		Screening 2	
D11S4076	80	86	80	80	86	86	84	90	88	88	80	88	80	76	80	88	80	88
D11S4205	193	193	193	193	193	191	197	189	193	193	197	193	197	195	197	193	197	193
D11S1883	108	106	116	110	104	104	116	118	106	108	116	104	108	110	116	104	116	110
Chr11-64-AC-110	105	101	105	111	103	107	105	103	105	95	105	105	105	103	105	105	105	103
Chr11-64-TG-110	103	97	103	103	99	105	103	109	103	99	103	103	103	95	103	85	103	109
D11S913	99	97	99	97	95	97	99	101	fail	fail	fail	fail	99	99	99	99	99	97
D11S1249	114	112	114	112	114	120	114	112	114	112	114	116	114	112	114	114	114	108
D11S1889	118	124	118	108	118	124	118	108	118	124	118	124	118	124	118	128	118	126
D11S987	97	99	97	95	97	99	97	101	97	105	97	113	97	105	97	105	97	105
Chr11-67-TG-107	101	105	101	103	101	99	101	103	101	95	101	103	101	105	101	103	101	103
D11S1337	290	282	290	284	290	296	290	282	290	280	290	282	290	280	290	282	290	282
D11S4178	248	248	248	252	248	232	248	252	248	248	248	248	248	254	248	208	248	248
D11S4095	108	102	108	108	108	108	108	108	108	102	108	102	108	102	108	114	108	108
D11S4136	112	104	112	102	112	120	112	118	112	110	112	112	104	116	110	114	112	114

FIPA UK, FIPA Romania, FIPA US (Italian), Sp India, Sp Mexico

Marker	FIPA UK		FIPA Romania		FIPA US (Italian)		Sp India		Sp Mexico	
D11S4076	88	86	88	84	74	86	86	92	80	88
D11S4205	193	193	193	193	193	195	193	193	193	193
D11S1883	108	120	106	108	104	104	108	118	104	104
Chr11-64-AC-110	105	95	103	107	105	103	103	103	103	103
Chr11-64-TG-110	87	109	103	105	99	109	87	101	81	111
D11S913	99	97	99	101	97	97	101	101	99	97
D11S1249	108	118	114	116	114	108	112	114	114	112
D11S1889	120	126	124	128	124	128	124	124	120	126
D11S987	99	103	99	107	99	103	103	105	99	111
Chr11-67-TG-107	103	103	101	101	101	105	101	105	101	103
D11S1337	282	282	290	290	282	282	280	282	284	284
D11S4178	248	248	248	252	248	254	248	252	248	236
D11S4095	108	110	106	106	102	106	102	102	108	102
D11S4136	110	110	108	110	108	108	114	118	112	118